Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the ...

"With 2 pivotal Phase III top line readouts for our global Phase III HCV program ahead of us, 2026 will be a catalyst-rich year for Atea" (Founder, Chairman, CEO & President Jean-Pierre Sommadossi).

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026C-FORWARD ...

A downtrend has been apparent in Atea Pharmaceuticals, Inc. (AVIR) lately with too much selling pressure. The stock has ...

Atea Pharmaceuticals Inc (AVIR) showcases robust financial health and strategic pipeline expansion, while navigating competitive pressures and global healthcare challenges.

Trial design can optimize a drug's chances for success. Patient-centered outcomes are the best endpoints for trials. In order to begin, one must compare the Merck and Atea trials. Both examined ...

Atea Pharmaceuticals is actively engaging with investors by hosting a live conference call and audio webcast to report financial results and provide a business update. The company is focused on the ...

To access the live conference call, participants may register here. The live audio webcast of the call will be available under “Events and Presentations” in the Investor Relations section of the Atea ...

Shares of Atea Pharmaceuticals (AVIR 1.60%) fell by as much as 14.4% in premarket trading Wednesday morning. The biotech's shares are sliding today in response to Roche's (RHHBY +1.29%) decision to ...